Comprehensive Psychiatry
Volume 44, Issue 1 , Pages 35-43, January 2003

Borderline personality disorder in major depression: Symptomatology, temperament, character, differential drug response, and 6-month outcome

From the Department of Psychological Medicine, Christchurch School of Medicine, Christchurch, New Zealand; Department of Psychiatry, Virginia Commonwealth University, Richmond, VA; and the Department of Psychiatry, Washington University at St. Louis, St. Louis, MO.

Abstract 

Among 183 depressed patients participating in a randomized long-term treatment trial of fluoxetine and nortriptyline, 30 patients had borderline personality disorder (BPD), 53 had other personality disorders (OPD), and 100 had no personality disorders (NPD). The borderline depressed patients had earlier age of onset of their depressions, more chronic depressions, more alcohol and cannabis comorbidity, and were more likely to have histories of suicide attempts and of self-mutilation. On self-report, patients with BPD and OPD reported more phobic symptoms, greater interpersonal sensitivity, and more paranoid ideation. Uniquely, BPD patients were more angry than OPD patients. BPD patients had high novelty seeking, high harm avoidance, low self-directedness, and low cooperativeness. Depressed patients with BPD did poorly in the short term if treated with nortriptyline rather than fluoxetine. After 6 months, those with BPD had a favorable outcome in regard to depressive symptoms, social adjustment, and even improvement in the character measure of self-directedness. Those with the poorest outcome were those with OPD.

No full text is available. To read the body of this article, please view the PDF online.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by a grant from the Health Research Council of New Zealand, and by an unrestricted grant from Eli Lilly (New Zealand) Ltd.

PII: S0010-440X(03)00021-X

doi:10.1053/comp.2003.50001

Comprehensive Psychiatry
Volume 44, Issue 1 , Pages 35-43, January 2003